In patients with localized SLL (Ann Arbor stage I) that progresses after initial radiation therapy or patients with advanced disease (Ann Arbor stages II-IV) with del (17p), treatment is based on the presence or absence of certain indications (see below) The presence of any of the following...
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
sepsis, and lower respiratory infections. Median time to onset of any grade infection was 3 months, with 75% of cases occurring within 6 months. Treat infections prior to initiation of COPIKTRA. Advise patients to report
INDICATIONS COPIKTRA® (duvelisib) is indicated for: The treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of systemic therapy. Limitations of Use: COPIKTRA is not indicated or recommended...
CLL and SLL are the most common form of leukemia, and patients receiving first-line BTK treatment tend to survive longer than those who do not receive treatment. Thus, CLL and SLL are core indications for BTK inhibitors. The world’s first BTK inhibitor, ibrutinib, was approved for marketing...
INDICATIONS RITUXAN®(rituximab) is a prescription medicine used to treat: Adults with Non-Hodgkin’s Lymphoma (NHL): alone or with other chemotherapy medicines. Children 6 months of age and older with mature B-cell Non-Hodgkin’s Lymphoma (NHL) and mature B-cell acute leukemia (B-AL): ...
Indications GAZYVA® (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). GAZYVA® (obinutuzumab), in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial...
we only begin treatment if patients have an indication for treatment. These indications include decline in the hemoglobin or platelet count or disease-related symptoms that we want to eliminate by providing treatment. Things are changing very quickly. We now have oral agents. There was a large ra...
Indications for treatment included progressive anemia and fatigue. First-line treatment options for this older patient with comorbidities include lower-intensity CIT, BTKi-based, and venetoclax-based regimens. Improved PFS, but not overall survival (OS), was demonstrated in phase 3 first-line trials...
Our findings suggest that, with the single analysis of the IGHV mutational status at CLL diagnosis, along with clinical and laboratory data, and without karyotype and TP53 data, clinicians will have prognostic and predictive indications for the first clinical treatment and appropriate follow-up of ...